Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infus...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., Kimby, Eva
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2009
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670786/
https://ncbi.nlm.nih.gov/pubmed/19015393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-09-177329
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker